- Title: Subtitle
- Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
- Creators
- Kerstin Wenzl - Mayo ClinicMatthew E Stokes - Bristol-Myers Squibb (Germany)Joseph P. Novak - Mayo ClinicSana Khan - Mayo ClinicMelissa A. Hopper - Mayo ClinicJordan E. Krull - Mayo ClinicAbigail Dropik - Mayo ClinicVivekananda Sarangi - Mayo ClinicRaphael Mwangi - Mayo ClinicMaria Ortiz - Bristol-Myers Squibb (Germany)Nicholas Stong - Bristol-Myers Squibb (India)C. Chris Huang - Bristol-Myers Squibb (Germany)Matthew J. Maurer - Mayo ClinicLisa M. Rimsza - Mayo Clinic in ArizonaBrian K. Link - University of IowaSusan L. Slager - Mayo ClinicYan Asmann - Mayo Clinic in FloridaPatrizia Mondello - Mayo ClinicRyan D. Morin - Simon Fraser UniversityStephen M. Ansell - Mayo ClinicThomas M. Habermann - Mayo ClinicAndrew L. Feldman - Mayo ClinicRebecca L. King - Mayo ClinicGrzegorz S. Nowakowski - Mayo ClinicJames R. Cerhan - Mayo ClinicAnita K. Gandhi - Bristol-Myers Squibb (India)Anne J. Novak - Mayo Clinic
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.1742-1744
- DOI
- 10.1182/blood-2022-159620
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984363158902771
Abstract
Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
Blood, Vol.140(Supplement 1), pp.1742-1744
11/15/2022
DOI: 10.1182/blood-2022-159620
Details
Metrics
30 Record Views